Since CFH variants are associated with increased risk of AMD, the Phase 2a ReGAtta study (NCT04643886) is being conducted to investigate whether intravitreal delivery of GEM103 (Gemini Therapeutics, Cambridge, MA, USA), a full-length recombinant CFH protein, is safe and may slow progression of non-exudative AMD in patients with loss-of-function CFH gene variants. The gene discussed is CFH; the disease is age-related macular degeneration.